当前位置: 首页 >> 检索结果
129. Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia.
作者: Jurre Y Siegers.;Ruopeng Xie.;Kimberly M Edwards.;Alexander M P Byrne.;Shu Hu.;Ruixuan Wang.;Sokhoun Yann.;Sarath Sin.;Songha Tok.;Kimlay Chea.;Sreyviseth Horm.;Chenthearath Rith.;Seangmai Keo.;Leakhena Pum.;Veasna Duong.;Heidi Auerswald.;Yisuong Phou.;Sonita Kol.;Andre Spiegel.;Ruth Harvey.;Sothyra Tum.;San Sorn.;Bunnary Seng.;Yi Sengdoeurn.;Darapheak Chau.;Savuth Chin.;Makara Hak.;Vanra Ieng.;Sarika Patel.;Peter Thielen.;Filip F Claes.;Nicola S Lewis.;Sovann Ly.;Erik A Karlsson.;Vijaykrishna Dhanasekaran.
来源: N Engl J Med. 2025年393卷16期1650-1652页 134. Common Diseases in Clinical Cohorts - Not Always What They Seem.
作者: Fedik Rahimov.;Benjamin M Jacobs.;John S Lee.;Naim A Mahi.;Andrew Blumenfeld.;Ammar J Alsheikh.;Ali Abbasi.;Mark Reppell.;Valerie L Pivorunas.;Haukur J Sigurðsson.;Stephen Sawcer.;Heath Guay.;Jeffrey F Waring.;Howard J Jacob.;Nizar Smaoui.
来源: N Engl J Med. 2025年393卷16期1589-1598页
Misdiagnosis or underdiagnosis of rare diseases in patients with diagnoses of common diseases can lead to delayed or inappropriate treatments, thereby complicating the management of both rare and common conditions. Despite advances in molecular diagnostic techniques, the effect of rare diseases on the diagnosis of common diseases in research and clinical trials has not been comprehensively investigated.
136. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.
作者: Javier Cortés.;Kevin Punie.;Carlos Barrios.;Sara A Hurvitz.;Andreas Schneeweiss.;Joohyuk Sohn.;Eriko Tokunaga.;Adam Brufsky.;Yeon Hee Park.;Binghe Xu.;Roberto Hegg.;Mafalda Oliveira.;Alessandra Fabi.;Natalya Vaksman.;Theresa Valdez.;Xinrui Zhang.;Catherine Lai.;Sara M Tolaney.; .
来源: N Engl J Med. 2025年393卷19期1912-1925页
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) have limited treatment options.
138. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.
作者: Wenfeng Fang.;Lin Wu.;Xiangjiao Meng.;Yu Yao.;Wei Zuo.;Wenxiu Yao.;Yanyan Xie.;Yu Zhang.;Jiuwei Cui.;Yongchang Zhang.;Xingya Li.;Wu Zhuang.;Jian Fang.;Qiming Wang.;Wei Jiang.;Kai Li.;Yuju Bai.;Yongzhong Luo.;Fang Ma.;Yan Yu.;Wei Zheng.;Zhentian Liu.;Bin Yang.;Rui Ma.;Yong Fang.;Runxiang Yang.;Liyan Jiang.;Jie Hu.;Jiacheng Yang.;Yina Diao.;Xiaoping Jin.;Junyou Ge.;Yunpeng Yang.;Li Zhang.
来源: N Engl J Med. 2025年
Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with EGFR-mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy.
139. Belzutifan for Advanced Pheochromocytoma or Paraganglioma.
作者: Camilo Jimenez.;Mikkel Andreassen.;Alice Durand.;Sophie Moog.;Andrew Hendifar.;Staffan Welin.;Francesca Spada.;Rohini Sharma.;Edward Wolin.;Joseph Ruether.;Rocio Garcia-Carbonero.;Martin Fassnacht.;Jaume Capdevila.;Jaydira Del Rivero.;Othon Iliopoulos.;Olivier Huillard.;Raymond Jang.;Knut Mai.;Elena Artamonova.;Andreas Hallqvist.;Tobias Else.;Amos Odeleye-Ajakaye.;Alexander Gozman.;Girish S Naik.;Alfredo Berruti.; .
来源: N Engl J Med. 2025年393卷20期2012-2022页
Pheochromocytoma and paraganglioma are neoplasms originating in the adrenal medulla and extraadrenal paraganglia, respectively. Most cases of metastatic pheochromocytoma and paraganglioma are driven by dysregulation of the hypoxia-inducible factor 2α (HIF-2α) pathway. Belzutifan is a HIF-2α inhibitor that may provide antitumor activity in patients with advanced pheochromocytoma or paraganglioma.
140. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
作者: Xinan Sheng.;Gongqian Zeng.;Cuijian Zhang.;Qingyun Zhang.;Jiasheng Bian.;Haitao Niu.;Jun Li.;Yanxia Shi.;Kai Yao.;Bin Hu.;Ziling Liu.;Hong Liao.;Zhixian Yu.;Baiye Jin.;Peng Zhao.;Tiejun Yang.;Xianling Liu.;Yang Qin.;Xueyi Xue.;Xin Gou.;Jian Huang.;Jiang Gu.;Xiaolong Qi.;Lu Zhang.;Guoxian Ma.;Beisong Liu.;Jianmin Fang.;Shusuan Jiang.;Zhisong He.;Aiping Zhou.;Jun Guo.; .
来源: N Engl J Med. 2025年
Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific disitamab vedotin as monotherapy and when combined with programmed cell death protein 1 (PD-1)-directed immunotherapy in this cancer.
|